| Date Filed | Type | Description |
| 02/14/2014 |
SC 13G/A
| MERITECH CAPITAL PARTNERS II LP reports a 0% stake in Solta Medical, Inc. |
| 02/13/2014 |
SC 13G/A
| Broadfin Capital, LLC reports a 4.2% stake in Solta Medical, Inc.. |
| 02/12/2014 |
SC 13G/A
| Longitude Capital Partners, LLC reports a 0% stake in Solta Medical, Inc. |
| 02/06/2014 |
SC 13G/A
| DELPHI VENTURES VII L P reports a 0.9% stake in Solta Medical, Inc. |
| 01/24/2014 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...|
Docs:
|
"Amended and Restated Certificate of Incorporation of Solta Medical, Inc",
"Amended and Restated By-laws of Solta Medical, Inc",
"VALEANT PHARMACEUTICALS INTERNATIONAL, INC. COMPLETES ACQUISITION OF SOLTA MEDICAL, INC. Laval, Quebec — January 23, 2014 — Valeant Pharmaceuticals International, Inc. today announced the completion of the previously announced transaction in which a wholly-owned subsidiary of Valeant Pharmaceuticals International would acquire Solta Medical, Inc. at a price of $2.92 per share in cash, or approximately $250 million in the aggregate. On January 23, 2014, Valeant announced that it had successfully completed the tender offer for all outstanding shares of common stock of Solta. Valeant announced that it had accepted for payment all shares validly tendered and not properly withdrawn as of the expiration time of the tender offer and would promptly pay for such shares, which represented approxim..." |
|
| 01/23/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/23/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/15/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/15/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/13/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/13/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 12/23/2013 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 12/23/2013 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 12/16/2013 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 12/16/2013 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Agreement and Plan of Merger, among Valeant Pharmaceuticals International, Sapphire Subsidiary Corp., Valeant Pharmaceuticals International, Inc. and Solta Medical, Inc",
"VALEANT PHARMACEUTICALS AGREES TO ACQUIRE SOLTA MEDICAL FOR $2.92 PER SHARE IN CASH Combination Creates a Global Leader in Aesthetics Transaction Values Solta at Approximately $250 Million Transaction Expected to Close in the First Quarter of 2014 Laval, Quebec and Hayward, Calif. — December 16, 2013 — Valeant Pharmaceuticals International, Inc. today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Solta Medical, Inc. for $2.92 per share in cash, which represents a 40% premium to Solta's closing share price on December 13, 2013, the last trading day prior to announcement, or a transaction value of approximately $250 million. The transaction is expected to close in the first quarter of 2014 and Valeant expects..." |
|
| 12/16/2013 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 12/10/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/03/2013 |
8-K
| Quarterly results |
| 11/15/2013 |
10-Q
| Quarterly Report for the period ended September 30, 2013 |
| 11/12/2013 |
8-K
| Quarterly results |
| 09/05/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/07/2013 |
10-Q
| Quarterly Report for the period ended June 30, 2013 |
| 08/06/2013 |
8-K
| Quarterly results |
| 06/07/2013 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 05/24/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/16/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 05/13/2013 |
SC 13G/A
| Growth Equity Opportunities Fund, LLC has filed a Schedule 13D for Solta Medical, Inc. |
| 05/06/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 05/06/2013 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 05/03/2013 |
10-Q
| Quarterly Report for the period ended March 31, 2013 |
| 05/03/2013 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 04/22/2013 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements |
| 04/17/2013 |
SC 13D
| Inlign CP III, LLC reports a 7.9% stake in Solta Medical, Inc. |
| 04/11/2013 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements |
|